Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
· Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) · Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline · Continuous improvement of acromegaly symptom and quality of life scores vs baseline · Study results reinforce previously reported interim results from ACROINNOVA 2[1] Lund, Sweden, 15 July 2024 — Camurus (NASDAQ STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the company’s once-monthly octreotide